2020 AABB Annual Meeting On-Demand

Oct 3, 2020 ‐ Oct 3, 2020



Access to the 2020 AABB Annual Meeting On-Demand sessions expires on December 31, 2022. Each session includes the on-demand recording and a downloadable MP3 audio file. Presentation handouts are not available/included.

Planning Committee Disclosures


Sessions

AM20-32: Late-breaking Oral Abstract Session

Oct 4, 2020 7:15pm ‐ Oct 4, 2020 8:15pm
Expiration Date: Dec 31, 2022

Credits: None available.

Oral abstract session on Late-breaking Oral abstracts

Speaker(s): Disclosures
  • Mars Stone, PhD : <p><br></p>
  • Bryan Spencer, PhD : Nothing to disclose
  • Sonia Bakkour, PhD : Nothing to disclose
  • Erin Meyer, DO, MPH : Nothing to disclose
  • Richard Gammon, MD : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-33: COVID-19 Convalescent Plasma (CCP) -- The Regulatory Landscape

Oct 5, 2020 10:00am ‐ Oct 5, 2020 11:00am
Expiration Date: Dec 31, 2022

Credits: None available.

During this live Q&A session, FDA’s Peter Marks and Nicole Verdun will answer questions about the regulatory framework for COVID-19 Convalescent Plasma (CCP). We will be taking live questions during the session and will try to get to as many of them as possible. 

Topics for discussion include:

- Timeline for implementation of the EUA.
- FDA’s use of temporary enforcement discretion .
- An update on the testing and labeling collections as high-titer or low-titer.
- Inventory management options such as retesting units collected under the National Expanded Access 

Program for use under the EUA or for shipment to the Surge Capacity Storage

Learning Objectives:
  • Review current regulatory process for CCP
  • Describe current regulations regarding CCP
  • Describe current regulatory landscape for CCP
Speaker(s):
  • Dr. Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, FDA
  • Dr. Nicole Verdun, MD, Director, Office of Blood Research and Review, FDA
Disclosures
  • Peter Marks, MD, PhD : Nothing to disclose
  • Nicole Verdun, MD : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-34: New Therapeutic Options for Patients with Sickle Cell Disease & Their Effect on the Transfusion Service

Oct 5, 2020 10:00am ‐ Oct 5, 2020 11:00am
Expiration Date: Dec 31, 2022

Credits: None available.

Sickle cell disease (SCD) is an inherited condition that affects about 100,000 individuals in the United States. This disorder is familiar to the transfusion medicine professionals (Physicians; Technologists) since it relies heavily on transfusion of blood products - either via simple transfusion or RBC exchange. In recent years (2017-2019), newer potentially disease-modifying options were identified and approved by the FDA for use including l-glutamin, anyipolomerization agents (voxelotor) and P-selectin inhibitors (crizanlizumab). Furthermore, gene therapy might be a real option for cure of the disease. This session will concentrate on the education of Transfusion Medicine professionals on these advances and their possible implications for clinical practice and subsequent potential effect on the transfusion service.

Learning Objectives:
  • Describe the recent advances in gene therapy as a potential cure for Sickle Cell Disease (SCD)
  • Summarize the newly approved drugs for SCD and their respective mechanism of action.
  • Recognize the advances in the practice of RBC exchange for SCD - indications as well as desired parameters ( Hematocrit ; FCR)
Speaker(s): Disclosures
  • John Tisdale : Nothing to disclose
  • Nicole Desimone, MD, MPH : Nothing to disclose
  • Deepa Manwani, MD : Consultant: Pfizer, Novartis, GBT, Forma Therapeutics; Research/Grant Support: FDA, NHLBI, Price Foundation, BBB, GBT
Standard: $25.00
Members: $20.00

AM20-35: Oral Abstract Session -- Pediatrics and Obstetrics

Oct 5, 2020 10:00am ‐ Oct 5, 2020 11:00am
Expiration Date: Dec 31, 2022

Credits: None available.

Oral abstract session on Pediatrics and Obstetrics

Learning Objectives:
  • Evaluate outcomes for pediatric trauma whole blood recipients.
  • Describe practice trends in newborn Direct Antiglobulin Testing (DAT) in North American blood banks.
  • Summarize how practice patterns influence massive transfusion protocol activation in obstetric hemorrhage.
Speaker(s): Disclosures
  • Andrew Fisher, MD : Nothing to disclose
  • Elizabeth Crowe, MD, PhD : Nothing to disclose
  • Lisa Hensch, MD : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-36: Oral Abstract Session -- COVID-19

Oct 5, 2020 11:15am ‐ Oct 5, 2020 12:15pm
Expiration Date: Dec 31, 2022

Credits: None available.

Oral abstract session on COVID-19

Learning Objectives:
  • Discuss the anticipation for the demand for convalescent plasma.
  • Discuss testing donors for COVID-19 antibodies.
  • Discuss ensuring staff safety and availability in the COVID-19 era.
  • Discuss treating the hypercoagulopathy of COVID-19.
Speaker(s): Disclosures
  • Emily Coberly, MD : Nothing to disclose
  • W. Russell, MS : Consultant: Terumo
  • Eilat Shinar, MD : Nothing to disclose
  • Amanda Herrmann, MD, PhD : <p><br></p>
Standard: $25.00
Members: $20.00

AM20-37: Temas Relevantes En El Area De Medicina Transfusional y Manejo Eficiente De Los Recursos Disponibles

Oct 5, 2020 11:15am ‐ Oct 5, 2020 12:15pm
Expiration Date: Dec 31, 2022

Credits: None available.

Este taller se dividira en dos secciones, en la primera parte se revisara el tema de hemorragia masiva y protocolos para controlar el sangramiento. Se discutira un caso clinico de un paciente con hemorragia y alloanticuerpos , el cual requiere una cantidad elevada de transfusiones, negativa para antigenos communmente presentes en la mayoria de los donantes. Veran tecnicas y protocolos usados en el laboratorio de inmunohematologia y el hospital para garantizar la disponibilidad de sangre en estos casos complejos. En la segunda parte del programa, se revisa el porque y la necesidad de la globalizacion de los servicios de banco de sangre y la eficiencia de este modelo en la preparacion de componentes y distribucion de sangre a los hospitals para asegurar la disponibilidad apropiada de los productos sanguineos.

This workshop will be divided into two sections, in the first part we will review the topic of massive hemorrhage and protocols to control bleeding. A clinical case of a patient with hemorrhage and alloantibodies will be discussed, which requires a high amount of transfusions, negative for antigens commonly present in the majority of donors. You will see techniques and protocols used in the immunohematology laboratory and the hospital to ensure blood availability in those complex cases. In the second part of the program, the reasoning and the need for the globalization of blood bank services and the efficiency of this model in the preparation of components and distribution of blood to hospitals to ensure the appropriate availability of products is reviewed.

Learning Objectives:
  • Review the clinical importance of massive transfusion and protocols to control bleeding. Revisar la importancia clinica de la transfusion masiva y protocolos para controlar el sangrado.
  • Describe the techniques and protocols used to treat patients with massive hemorrhage and antibodies. Describir las tecnicas y protocolos usados para tratar pacientes con hemorragia masiva y anticuerpos.
  • Discuss the globalization of blood bank programs and the advantages of the model. Discutir la globalizacion de los programas de banco de sangre y las ventajas del modelo.
Speaker(s): Disclosures
  • Alexander Indrikovs : Nothing to disclose
  • Lynsi Rahorst, MHPE, MT(ASCP)SBB : Nothing to disclose
  • Alicia Prichard, MT(ASCP)SBB, MBA : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-38: The Thin Line Between Advancement or Exploitation…the Role of the “Super Donor” in Allogeneic Cell Therapy

Oct 5, 2020 11:15am ‐ Oct 5, 2020 12:15pm
Expiration Date: Dec 31, 2022

Credits: None available.

Discover why reliance on a small subset of “super donors” could introduce risk and ignite ethical considerations for cell and gene therapy companies seeking sustainable growth and scalability.

Learning Objectives:
  • Describe how known and unknown inherent differences in human beings and populations can impact starting material
  • Describe how access to a large pool of diverse donors is essential for current and future needs
  • Discover how the use/overuse of “super donors” involves not only technical, regulatory and medical issues, but also ethical and legal issues
  • Discuss strategic solutions for sustainable cell and gene therapy development and growth
Speaker(s): Disclosures
  • Joy Aho : Nothing to disclose
  • Jason Dehn, MPH : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-39: Practical Hemostasis in Transfusion Medicine: Test Interpretation & Therapeutic Strategies for Coagulation Conundrums

Oct 5, 2020 2:30pm ‐ Oct 5, 2020 3:30pm
Expiration Date: Dec 31, 2022

Credits: None available.

On a day-to-day basis, transfusion medicine and apheresis practitioners are asked to play critical and often acute care roles as consultants for complex issues related to hemostasis and thrombosis. The intricacy of coagulation assays and the blood bank and pharmaceutical tools available for managing bleeding disorders have all expanded dramatically over the past 5-10 years. Therefore, in order to provide accurate hemostasis/thrombosis consultation, providers must have an up-to-date understanding of common coagulation assays and how their results inform transfusion and apheresis management. The aim of this session is to familiarize practitioners with common coagulation problems, with an emphasis on test interpretation to improve consultation and management of bleeding/clotting disorders from the transfusion medicine and apheresis perspectives. We will focus on three critical areas of hemostasis/thrombosis and intend to: 1) familiarize practitioners with the current concepts of congenital bleeding disorders, with a particular emphasis on diseases that are primarily managed via blood components (e.g., Factor V deficiency, FXI deficiency) and inform learners on how coagulation assays can be used to guide therapy for these disorders, 2) discuss the clinical problem of lupus anticoagulants (LACs), with an emphasis on demystifying the highly complicated testing platforms associated with these disorders and to highlight roles blood bank and apheresis services play in managing complications of LACs, and 3) examine the problem of cardiac surgery-associated bleeding, including exploring its pathophysiology, investigating acute care assays which may be helpful in its assessment, and recommending practical transfusion strategies for acquired platelet function abnormalities.

Learning Objectives:
  • Distinguish congenital bleeding disorders that are managed primarily with blood bank-derived components, including test interpretation and associated transfusion strategies
  • Discuss the clinical problem of lupus anticoagulants (LACs), including pearls and pitfalls in test interpretation and blood bank/apheresis management of hemostasis disorders associated with LACs
  • Describe the problems of cardiac surgery-associated bleeding, including review of acute care testing modalities for the hemorrhaging patient and transfusion approaches to reversal of thrombocytopathy
Speaker(s): Disclosures
  • Christopher Tormey, MD : Nothing to disclose
  • Lawrence Williams, MD : Nothing to disclose
  • Geoffrey Wool, MD, PhD : Consultant/Speaker Bureau/Honoraria: Diagnostica Stago
Standard: $25.00
Members: $20.00

AM20-40: Platelet Inventory Management for Transfusion Services

Oct 5, 2020 2:30pm ‐ Oct 5, 2020 3:30pm
Expiration Date: Dec 31, 2022

Credits: None available.

Blood product inventory management is essential for improving patient care and mitigating the increasing cost of healthcare. On September 30, 2019, the US FDA published a Guidance for Industry titled “Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion.” This guidance offers 9 options for reducing the risk of bacterial contamination of platelets, but may decrease rather than increase platelet availability. In this setting, effective platelet inventory management (PIM) is more important than ever.

Nancy Dunbar will review evidence based platelet transfusion triggers, examine methods for prospective order auditing, and explore strategies for PIM during times of shortage.

Tho Pham will cover how to use big data and computer modeling to enhance PIM. While platelet usage can be highly variable, big data can be mined to identify relationships to build a statistical model capable of forecasting platelet demand. This analysis can be used to guide platelet ordering to decrease expiration, reduced wastage, and avoid shortages.

Neil Shah will address the role of clinical decision support (CDS) for platelet ordering to improve PIM. Aspects of implementing a successful CDS program, starting from clinical acceptance of best-practice evidence and establishing local guidelines, to building and implementing a successful CDS program will be described.

Learning Objectives:
  • Compare different methods for prospective order auditing as well as other strategies for platelet inventory management to better fare during times of platelet shortage
  • Appreciate how analysis of big data can be used to predict platelet supply and demand
  • Apply how to implement clinical decision support for platelet ordering to improve platelet inventory management
Speaker(s):
  • Dr. Nancy M. Dunbar, MD, Associate Professor for the Dept. of Pathology and Lab Medicine; Associate Medical Director of Transfusion Service and Medical Director of Blood Bank, Dartmouth-Hitchcock Medical Center
  • Tho D. Pham, MD, Clinical Assistant Professor; Chief Medical Officer, Stanford University School of Medicine
  • Dr. Neil Shah, MD, Stanford University Medical Center
Disclosures
  • Nancy Dunbar, MD : Consultant: Verax
  • Tho Pham, MD : Nothing to disclose
  • Neil Shah, MD : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-41: Engineered Microphysiological Systems -- AABB/TERMIS Joint Session

Oct 5, 2020 2:30pm ‐ Oct 5, 2020 3:30pm
Expiration Date: Dec 31, 2022

Credits: None available.

Presented in collaboration with Be The Match BioTherapies® 

Microphysiological systems, also often referred to as “organ-on-a-chip," are two- or three-dimensional constructs using human cells designed to model the spatial, chemical, structural, and physiological elements of in vivo cellular environments. This is currently one of the hottest research areas in the development of translational applications. Faculty in this session will explore various applications including drug screening and toxicology, tumor models for cancer diagnosis, and models for human development and diseases.

Learning Objectives:
  • Discuss the basics of organ-on-a-chip-based microphysiological systems.
  • Review the benefits and limitations of using this approach.
  • Review regulatory and commercialization considerations in product development.
Speaker(s): Disclosures
  • Shay Soker, PhD : Nothing to disclose
  • George Truskey, PhD : Nothing to disclose
  • Y. Zhang : Consultant: Allevi, Inc.
Standard: $25.00
Members: $20.00
Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content